BMRN

#695
BioMarin Pharmaceuticals Inc
61.73
+2.30%
Sector:
Base:
Profit Currency:
Daily Range
61.73
61.73
Year Range
50.76
73.51
Daily Change
+2.30%
Monthly Change
+8.81%
6 month change
+5.58%
Year Change
-10.69%
Previous Close
60.34
Open
61.73
Bid
Ask
Low
61.73
High
61.73
Volume
168
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 11.85 B
  • Employee 3 040
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
—
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

News